Azelis Group stock
AZE.BRBRUAzelis Group N.V., Basic MaterialsISIN BE0974400328
59Score 59 out of 100, Neutral
Price and trend
62 / 100
Price history
+21% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 63).
The price is 11% below its 52-week high. Largest decline in 5 years: 76% (November 2021 to March 2026).
Chart figures for advanced users
- SMA 50$13.50
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.73
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)63
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.73
- The lowest closing price of the last twelve months.
- Resistance$14.93
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Azelis Group N.V. belongs to the Chemicals (Specialty) industry (Belgium) and, with a market value of $3.25B, is number 75 of 108 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.6B (down 2.5% year on year) and earnings of $123.72M (down 38.5%).
- For fiscal 2026, analysts expect on average revenue of $4.73B (up 2.8%) and adjusted earnings per share of $0.91 (up 13.1%).
Show more
- MEQIRI Score 59 out of 100 (Neutral): rank 216 of 467 in Basic Materials, median 58.
- The P/E is 25.9 (Chemicals (Specialty) median 24.4, own median of recent years 29.1).
- Our model puts fair value at $18.66, with the price 30% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 242% of earnings over the last 12 months.Fundamentals 77
- Below fair valuePrice 30% below the fair value of $18.66.Valuation 73
- Growing faster than its industryRevenue up 12.1% a year since 2020, Chemicals (Specialty) median 6%.Growth 72
Weaknesses
- Interest barely coveredOperating profit covers interest only 2.4 times.Stability 61
Its standout strengths are fundamentals and valuation, while capital allocation and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $14.35 and expensive above $26.65 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $24.76 (cash-flow model) and $12.55 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $16.94, at 7.8% it would be $21.04.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (24.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 29.8% on the twelve months before. Revenue has grown strongly since 2018, at around 49% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 12%, operating 7%, net 3%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 98 days
- Last reported
- 30 Jul 2026EPS reported $0.57 (expected $0.58)in line with expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 3.5% since 15 Oct 2026.
- Earnings per share
- $0.91+3.5%
- Revenue
- $4.73B+0.6%
- Earnings per share
- $1.00+3.3%
- Revenue
- $4.9B+0.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Azelis Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 59
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- AvientAVNT $4.24B61
- CabotCBT $3.71B61
- AshlandASH $3.51B53
- HEXPOLHPOL-B.ST $3.31B68
- HawkinsHWKN $3.16B69
- CalumetCLMT $3.15B47
- WD-40WDFC $2.94B73
- H.B. FullerFUL $2.73B53
ETFs that hold Azelis Group
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.62% | 0.40% | €575.19M |
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.54% | 0.28% | €627.81M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.28% | 0.30% | €810.11M |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.25% | 0.23% | €319.31M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.21% | 0.30% | €3.43B |
| WisdomTree Europe Equity UCITS ETF EUR AccWTDF | 0.18% | 0.32% | €131.6M |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.09% | 0.34% | €16.87M |
| Invesco RAFI Europe Fundamental Value UCITS ETF6PSC | 0.04% | 0.39% | €37.4M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 5 Jun 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.